Onco Actu du 3 octobre 2018

	2.11 Etiologie - Alimentation
Processed meat 'linked to breast cancer' [BBC News] Experts recommend caution about the findings and say the actual risk for individual women is "very small".
	3. Prévention
Australia on track to wipe out cervical cancer within 20 years [The Guardian] Research says disease will soon be a rarity thanks to screening and school immunisation.
Cervical cancer: Australia 'to be first to eliminate disease' [BBC News] The study predicted that annual cases in Australia would drop to four in 100,000 by 2035 - a potential elimination threshold, the researchers suggested. The WHO has not yet established such a standard for when cervical cancer becomes so uncommon it is deemed eliminated.
	3.1.1 Prévention - Tabac - e-cigs
F.D.A. Seizes Documents From Juul Headquarters [NY Times] A RAND Corporation study of 2,039 Californians from ages 16 to 20 beginning in 2015 through 2017, released Tuesday, offered new evidence for concern about teenage vaping.
FDA seizes documents from Juul in latest e-cigarette crackdown [Reuters] The FDA’s regulation of e-cigarettes has come under the spotlight as Juul’s popularity surged.
	3.3 Prévention - Vaccins
Nearly 14 Million Additional Adolescents Need to Be Vaccinated against HPV to Reach Public Health Goal [ACS] The authors say a disproportionate percentage of males, whites, and privately insured adolescents are not up to date with HPV vaccination.
	4.12 Biopsies liquides
Bringing personalized oncology to cancer prediction — and prevention [Fred Hutch] What Bielas ultimately envisions is a quick and easy blood test that gives each person a window into how quickly their DNA is mutating. This would allow doctors to more closely monitor an individual for cancer, or perhaps help that patient make a risk-reducing change to their environment, such as giving up smoking. But that’s still years away.
	4.9 Dép., diag. & prono. - Sein
Many women never heard of a 'baseline mammogram' [Reuters] The research team found that 46 percent of the women hadn’t heard the term “baseline mammogram.” And 61 percent didn’t think having a baseline mammogram was important for decreasing the cost, time, discomfort and unnecessary biopsies that may occur when mammograms are incorrectly interpreted as abnormal.
	5. Traitements
Conquering cancer by attacking the disease’s genetic abnormalities [Washington Post] Tumor profiling is becoming a cornerstone of oncology treatment, but the practice has become a contested issue in the field.
	5.10 Traitements - Essais
Examining the truth behind clinical trial costs [PhRMA] Notably absent from the study findings were the R&D costs associated with the nearly 90 percent of medicines that never attain U.S. Food and Drug Administration approval.
Are drug R&D costs exaggerated for effect? Researchers peg the median price of pivotal success at an economical $19M [EndPoints] PhRMA took a look at these numbers, though, and immediately bristled at the implications. The study, says a spokesperson, ignores the full range of costs that go into developing a new drug, from preclinical through approval. And what about all the failures companies have to endure along the way? That adds enormously to the cost of drug development, says a spokesperson.
	5.12.1 Immunothérapies - partenariats
Giving it a GO: Giant Roche selects a tiny player at LabCentral for its next cancer R&D partner [EndPoints] If it works, they could open up a path to new and better immunotherapies, with CAR-T joining a group of drug types that includes antibody-drug conjugates as well as T-cell bispecifics and more.
	5.12.8 Immunothérapies - Economie
Belldegrun and Chang groom their biotech unicorn Allogene for a monster $288M — or so — IPO [EndPoints] Today the pair running the biotech startup Allogene, a CAR-T company looking to make history pioneering off-the-shelf cell therapeutics, outlined plans to sell 16 million shares in the company at $16 to $18 a share. That’s $288 million at the top of the range — though these 2 may not be satisfied with anything less than more.
The Nobel Prize is a reminder of the outrageous cost of curing cancer [Vox] In a recent analysis, published in the journal PNAS, researchers found that American tax dollars helped fund the basic research that went into every single one of the drugs approved by the Food and Drug Administration between 2010 and 2016 — including several cancer immunotherapies. All told, $100 billion in National Institutes of Health research grants helped advance the science behind those drugs.
	6.10.1 Politiques (USA)
Trump administration moves to weaken guidelines on radiation, suggesting some is healthy [STAT] The radiation regulation is supported by Steven Milloy, a Trump transition team member for the EPA who is known for challenging widely accepted ideas about manmade climate change and the health risks of tobacco. He has been promoting Calabrese’s theory of healthy radiation on his blog.
	6.12 Ethique
Memorial Sloan Kettering, you’ve betrayed my trust [STAT] With all due respect, I think an institution that can so ably tackle the complexities of cancer ought to be able to master disclosure requirements.
Memorial Sloan Kettering’s Chief Executive Resigns From Merck’s Board of Directors [NY Times] Dr. Thompson, 65, received $300,000 in compensation from Merck in 2017, according to company financial filings. He was paid $70,000 in cash by Charles River in 2017, plus $215,050 in stock.
	6.14 Prix Nobel
Cancer immunologists scoop medicine Nobel prize [Nature] Immunologist Jerome Galon of the French national biomedical research agency, INSERM, in Paris, was not surprised by the committee’s decision to award the prize to Honjo and Allison. “I think they really deserve it,” he says. “You can always multiply and have many other people, but these are the obvious two first choices.”